CINECA IRIS Institutional Research Information System

LONARDI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.662
AS - Asia 1.650
EU - Europa 849
SA - Sud America 348
AF - Africa 105
OC - Oceania 1
Totale 5.615
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.582
SG - Singapore 588
CN - Cina 416
IT - Italia 275
BR - Brasile 272
HK - Hong Kong 227
VN - Vietnam 197
SE - Svezia 104
DE - Germania 96
GB - Regno Unito 90
FR - Francia 56
CA - Canada 47
IN - India 45
FI - Finlandia 44
RU - Federazione Russa 43
CI - Costa d'Avorio 36
BG - Bulgaria 35
AR - Argentina 30
TR - Turchia 27
NL - Olanda 26
BD - Bangladesh 24
JP - Giappone 23
IQ - Iraq 20
NG - Nigeria 18
SN - Senegal 16
MX - Messico 15
ID - Indonesia 13
AT - Austria 12
EC - Ecuador 12
PL - Polonia 12
SA - Arabia Saudita 11
CO - Colombia 9
PK - Pakistan 9
ZA - Sudafrica 9
CZ - Repubblica Ceca 8
ES - Italia 8
UA - Ucraina 8
EG - Egitto 7
KR - Corea 7
LT - Lituania 7
PE - Perù 7
UZ - Uzbekistan 7
PH - Filippine 6
VE - Venezuela 6
PY - Paraguay 5
MY - Malesia 4
NP - Nepal 4
PA - Panama 4
TN - Tunisia 4
AZ - Azerbaigian 3
ET - Etiopia 3
JO - Giordania 3
KE - Kenya 3
KZ - Kazakistan 3
MA - Marocco 3
RO - Romania 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BO - Bolivia 2
BY - Bielorussia 2
CG - Congo 2
CL - Cile 2
CR - Costa Rica 2
DK - Danimarca 2
EE - Estonia 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
IR - Iran 2
KG - Kirghizistan 2
NI - Nicaragua 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AI - Anguilla 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
GD - Grenada 1
HR - Croazia 1
IE - Irlanda 1
IL - Israele 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MM - Myanmar 1
MN - Mongolia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
SI - Slovenia 1
Totale 5.615
Salva come PNG Salva come JPEG
Città #
Singapore 340
Ashburn 309
Hong Kong 222
Santa Clara 200
San Jose 185
Woodbridge 144
Dallas 140
Fairfield 132
Chandler 128
Ann Arbor 116
Houston 111
Boardman 109
Shanghai 99
New York 76
Beijing 71
Seattle 57
Los Angeles 56
Ho Chi Minh City 53
Wilmington 51
Council Bluffs 46
Cambridge 40
Florence 39
Hanoi 38
London 38
Abidjan 36
Sofia 35
Princeton 29
Lawrence 27
São Paulo 27
Lauterbourg 25
Frankfurt am Main 23
Helsinki 21
Colorado Springs 20
Medford 20
Munich 20
Ogden 20
Milan 19
Pisa 19
Tokyo 19
Serra 18
Lagos 17
Dakar 16
Lancaster 16
Istanbul 15
Redondo Beach 14
Montreal 13
San Diego 13
Bremen 12
Buffalo 12
Chennai 12
Ottawa 12
Rome 12
Baghdad 11
Cascina 11
Turku 11
Da Nang 10
Dearborn 10
Des Moines 10
Düsseldorf 10
Hefei 10
Orem 10
Warsaw 10
Baltimore 9
Nuremberg 9
Haiphong 8
Toronto 8
Mexico City 7
Phoenix 7
Poplar 7
Quanzhou 7
Seoul 7
Columbus 6
Curitiba 6
Denver 6
Redwood City 6
Tashkent 6
Verona 6
Belo Horizonte 5
Brooklyn 5
Bắc Ninh 5
Chicago 5
Kent 5
Manchester 5
Sorocaba 5
Vienna 5
Washington 5
Amsterdam 4
Ankara 4
Atlanta 4
Bogotá 4
Cairo 4
Dong Ket 4
Florianópolis 4
Fortaleza 4
Fuzhou 4
Karachi 4
Lahore 4
Lima 4
Mumbai 4
Nanjing 4
Totale 3.651
Salva come PNG Salva come JPEG
Nome #
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 279
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 179
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer 178
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 170
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 169
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 168
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 165
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 160
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 148
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 139
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 134
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 134
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 133
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 133
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 132
null 129
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 129
Epstein-Barr virus associated gastric dysplasia: a new rare entity? 126
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 124
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 121
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 119
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 119
Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer 116
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 115
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 112
null 111
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 110
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 107
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 99
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 97
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 97
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 94
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study 89
The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer 88
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial 87
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 84
Gastric cancer: Translating novels concepts into clinical practice 79
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 79
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 78
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 75
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer 69
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 67
null 65
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 61
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers 60
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 54
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 44
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 43
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 39
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 37
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 34
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 33
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 33
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 32
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study 26
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 18
Totale 5.720
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.878
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.878
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022217 2 2 0 6 29 39 5 6 15 22 20 71
2022/2023455 35 80 42 31 52 38 7 24 97 1 40 8
2023/2024273 15 20 46 10 26 47 28 8 7 8 31 27
2024/20251.493 12 83 32 65 141 211 99 76 151 158 149 316
2025/20262.340 148 253 220 227 233 245 364 165 139 217 81 48
2026/202715 15 0 0 0 0 0 0 0 0 0 0 0
Totale 5.720